CANCER VACCINES

The present disclosure provides (a) isolated immunogenic TAA polypeptides (i.e., an immunogenic MUC1 polypeptides, an immunogenic MSLN polypeptides, and an immunogenic TERT polypeptides), (b) isolated nucleic acid molecules encoding one or more immunogenic TAA polypeptides, (c) vaccine compositions...

Full description

Saved in:
Bibliographic Details
Main Authors BINDER, Joseph John, CHO, Helen Kim, GURU, Siradanahalli, JOOSS, Karin Ute, MARTINIC, Marianne Marcela Andrea, FALCONER, Derek John, COCKLE, Paul Jason, WILLS, Kenneth Nelson
Format Patent
LanguageEnglish
French
German
Published 28.11.2018
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:The present disclosure provides (a) isolated immunogenic TAA polypeptides (i.e., an immunogenic MUC1 polypeptides, an immunogenic MSLN polypeptides, and an immunogenic TERT polypeptides), (b) isolated nucleic acid molecules encoding one or more immunogenic TAA polypeptides, (c) vaccine compositions comprising an immunogenic TAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic TAA polypeptide, and (d) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions.
Bibliography:Application Number: EP20170702951